[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 96, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 963111, "exercisedValue": 0, "unexercisedValue": 2049802}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 37, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 595515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 676166, "exercisedValue": 0, "unexercisedValue": 234059}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 57, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 59, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Dewees", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Feng  Xu", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Subhashis  Banerjee M.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.59, "open": 1.61, "dayLow": 1.6, "dayHigh": 1.64, "regularMarketPreviousClose": 1.59, "regularMarketOpen": 1.61, "regularMarketDayLow": 1.6, "regularMarketDayHigh": 1.64, "payoutRatio": 0.0, "forwardPE": -0.46666667, "volume": 78155, "regularMarketVolume": 78155, "averageVolume": 383198, "averageVolume10days": 434950, "averageDailyVolume10Day": 434950, "bid": 1.58, "ask": 1.65, "bidSize": 1, "askSize": 1, "marketCap": 39224592, "fiftyTwoWeekLow": 1.47, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.987, "twoHundredDayAverage": 6.838325, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -115178688, "profitMargins": 0.0, "floatShares": 5916827, "sharesOutstanding": 24363100, "sharesShort": 1235882, "sharesShortPriorMonth": 1395447, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0507, "heldPercentInsiders": 0.1999, "heldPercentInstitutions": 0.89731, "shortRatio": 9.9, "shortPercentOfFloat": 0.127, "impliedSharesOutstanding": 24363100, "bookValue": 6.928, "priceToBook": 0.2323903, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -71721000, "trailingEps": -6.04, "forwardEps": -3.45, "enterpriseToEbitda": 1.589, "52WeekChange": -0.86583334, "SandP52WeekChange": 0.12677538, "quoteType": "EQUITY", "currentPrice": 1.61, "targetHighPrice": 19.0, "targetLowPrice": 10.0, "targetMeanPrice": 15.4, "targetMedianPrice": 18.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 165963008, "totalCashPerShare": 6.812, "ebitda": -72489000, "totalDebt": 13996000, "quickRatio": 13.618, "currentRatio": 13.93, "totalRevenue": 0, "debtToEquity": 8.292, "revenuePerShare": 0.0, "returnOnAssets": -0.33295, "returnOnEquity": -0.68136, "grossProfits": 0, "freeCashflow": -36413624, "operatingCashflow": -59787000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "averageDailyVolume3Month": 383198, "fiftyTwoWeekLowChange": 0.13999999, "fiftyTwoWeekLowChangePercent": 0.09523808, "fiftyTwoWeekRange": "1.47 - 17.31", "fiftyTwoWeekHighChange": -15.7, "fiftyTwoWeekHighChangePercent": -0.9069902, "fiftyTwoWeekChangePercent": -86.583336, "earningsTimestamp": 1746705601, "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754569800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -6.04, "epsForward": -3.45, "epsCurrentYear": -2.94, "priceEpsCurrentYear": -0.54761904, "fiftyDayAverageChange": -0.37699997, "fiftyDayAverageChangePercent": -0.18973325, "twoHundredDayAverageChange": -5.228325, "twoHundredDayAverageChangePercent": -0.7645622, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "postMarketChangePercent": 1.8633523, "postMarketPrice": 1.64, "postMarketChange": 0.029999971, "regularMarketChange": 0.02, "regularMarketDayRange": "1.6 - 1.64", "fullExchangeName": "NasdaqGM", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1751570984, "regularMarketTime": 1751562001, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.25786, "regularMarketPrice": 1.61, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-05"}]